Loading
NRM-823 is an experimental T cell engager from Normunity, in phase 1 trials for head and neck squamous cell carcinoma, oesophageal squamous cell carcinoma and oesophageal adenocarcinoma and other cancers.
NRM-823 is a T cell engager (bispecific) from Normunity. A first-in-class T cell engager that binds a novel tumour-specific target which the company says is expressed on multiple types of solid tumours and absent in normal systemic tissues. The company has not named the target. Its furthest stage is phase 1, for head and neck squamous cell carcinoma, oesophageal squamous cell carcinoma, oesophageal adenocarcinoma and gastric adenocarcinoma. ClinicalTrials.gov registers it in one study linked below. First patient dosed in the phase 1a/1b study, announced 5 November 2025; registry status RECRUITING. Whether it works in people has not been established unless a trial below reports it.
A first-in-class T cell engager that binds a novel tumour-specific target which the company says is expressed on multiple types of solid tumours and absent in normal systemic tissues. The company has not named the target.
1.One arm of NRM-823 binds its target on the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"NRM-823" OR ABSTRACT:"NRM-823") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NRM-823, not a curated reading list.
Shares Endometrial cancer, Head and neck squamous cell carcinoma, Ovarian cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Oesophageal squamous cell carcinoma, Endometrial cancer, Gastric & gastro-oesophageal junction cancer, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Oesophageal squamous cell carcinoma, Oesophageal and junctional adenocarcinoma, Gastric & gastro-oesophageal junction cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Endometrial cancer, Gastric & gastro-oesophageal junction cancer, Head and neck squamous cell carcinoma, Ovarian cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Ovarian cancer, Triple-negative breast cancer (TNBC), Non-small-cell lung cancer and the tag pipeline.
Shares Endometrial cancer, Head and neck squamous cell carcinoma, Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Head and neck squamous cell carcinoma, Ovarian cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Oesophageal squamous cell carcinoma, Cervical cancer, Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/